Sofwave Medical Ltd. ((IL:SOFW)) announced an update on their ongoing clinical study.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Sofwave Medical Ltd. is conducting a clinical study titled ‘Safety and Efficacy of SofWave Treatment to Lift Facial Lax Skin and Improve Facial Wrinkles Using Precise and Lift Applicators.’ The study aims to evaluate the safety and effectiveness of the Sofwave treatment in addressing facial lax skin and wrinkles, which is significant for advancing non-invasive cosmetic procedures.
The intervention being tested is the Sofwave System, a device that uses high-intensity, non-focused ultrasonic energy to treat tissues. The system includes an applicator and a console designed to improve skin laxity and wrinkles.
This study is designed as an open-label, non-randomized, single-arm trial with masked evaluation. It involves a single group receiving the treatment, focusing on treatment as its primary purpose, without any masking.
The study began on March 20, 2024, with the latest update submitted on May 12, 2025. These dates indicate the study’s progression and ongoing nature, with primary completion and estimated completion dates yet to be disclosed.
The update on this study could positively influence Sofwave Medical Ltd.’s stock performance by enhancing investor confidence in their innovative treatments. As the cosmetic treatment market is competitive, advancements in non-invasive procedures can provide a competitive edge.
The study is ongoing, and further details are available on the ClinicalTrials portal.